/ / MOR202C206
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
PLS AVAILABLE
Details
Development Status
In Development
Study Type
Interventional
Results Available
Yes
Study Dates
08/2021 - 05/2024
Enrollment
54
Study Drug
Placebo, felzartamab
Summary
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa
trial and dose evaluation trial of felzartamab in IgAN
Study Results
View and download the Results Summaries with the results of this completed study.
Plain Language Summary
PDF Document
View study results on registries
